Shalini Sharp

Shalini Sharp has been a member of our Board of Directors since 2018. She has more than 25 years of experience in the life sciences industry and was most recently the Chief Financial Officer at Ultragenyx, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases. In this role, she was responsible for leading the company’s corporate finance, strategy, and information technology functions. Prior to Ultragenyx, Ms. Sharp was Chief Financial Officer at Agenus Inc, a publicly traded biotechnology company focused on cancer immunotherapies. Before that, she worked in corporate strategy at Elan Pharmaceuticals, management consulting at McKinsey & Company, and investment banking at Goldman Sachs, always in the pharmaceutical and medical device space. Ms. Sharp also serves as a board member at Organon & Co., Mirati Therapeutics, Neurocrine Biosciences, Sutro Biopharma, and TB Alliance. She holds both a BA, magna cum laude, and MBA from Harvard University.